Literature DB >> 26318878

A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes.

Brian A McCarthy1, Sophia Yancopoulos1, Mike Tipping2, Xiao-Jie Yan1, Xue Ping Wang1, Fiona Bennett3, Wentian Li1, Martin Lesser1, Santanu Paul1, Erin Boyle1, Carolina Moreno1, Rosa Catera1, Bradley T Messmer4, Giovanna Cutrona5, Manlio Ferrarini6, Jonathan E Kolitz1,7, Steven L Allen1,7, Kanti R Rai1,7, Andrew C Rawstron3, Nicholas Chiorazzi8,9.   

Abstract

Chronic lymphocytic leukemia (CLL) is a clonal disease of B lymphocytes manifesting as an absolute lymphocytosis in the blood. However, not all lymphocytoses are leukemic. In addition, first-degree relatives of CLL patients have an ~15 % chance of developing a precursor condition to CLL termed monoclonal B cell lymphocytosis (MBL), and distinguishing CLL and MBL B lymphocytes from normal B cell expansions can be a challenge. Therefore, we selected FMOD, CKAP4, PIK3C2B, LEF1, PFTK1, BCL-2, and GPM6a from a set of genes significantly differentially expressed in microarray analyses that compared CLL cells with normal B lymphocytes and used these to determine whether we could discriminate CLL and MBL cells from B cells of healthy controls. Analysis with receiver operating characteristics and Bayesian relevance determination demonstrated good concordance with all panel genes. Using a random forest classifier, the seven-gene panel reliably distinguished normal polyclonal B cell populations from expression patterns occurring in pre-CLL and CLL B cell populations with an error rate of 2 %. Using Bayesian learning, the expression levels of only two genes, FMOD and PIK3C2B, correctly distinguished 100 % of CLL and MBL cases from normal polyclonal and mono/oligoclonal B lymphocytes. Thus, this study sets forth effective computational approaches that distinguish MBL/CLL from normal B lymphocytes. The findings also support the concept that MBL is a CLL precursor.

Entities:  

Keywords:  B lymphocytes; Chronic lymphocytic leukemia; Diagnosis; Gene expression

Mesh:

Substances:

Year:  2015        PMID: 26318878     DOI: 10.1007/s12026-015-8688-3

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  49 in total

Review 1.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Authors:  Victoria Del Gaizo Moore; Jennifer R Brown; Michael Certo; Tara M Love; Carl D Novina; Anthony Letai
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia.

Authors:  Lynn R Goldin; Magnus Björkholm; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

Review 4.  Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management.

Authors:  T D Shanafelt; P Ghia; M C Lanasa; O Landgren; A C Rawstron
Journal:  Leukemia       Date:  2010-01-21       Impact factor: 11.528

5.  LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.

Authors:  Albert Gutierrez; Renee C Tschumper; Xiaosheng Wu; Tait D Shanafelt; Jeanette Eckel-Passow; Paul M Huddleston; Susan L Slager; Neil E Kay; Diane F Jelinek
Journal:  Blood       Date:  2010-07-01       Impact factor: 22.113

Review 6.  Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.

Authors:  Michael Hallek
Journal:  Am J Hematol       Date:  2015-05       Impact factor: 10.047

Review 7.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

Review 8.  Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patients.

Authors:  Andy Rawstron; Peter Hillmen; Richard Houlston
Journal:  Semin Hematol       Date:  2004-07       Impact factor: 3.851

9.  Identification of a global gene expression signature of B-chronic lymphocytic leukemia.

Authors:  Diane F Jelinek; Renee C Tschumper; Gustavo A Stolovitzky; Stephen J Iturria; Yuhai Tu; Jorge Lepre; Nigam Shah; Neil E Kay
Journal:  Mol Cancer Res       Date:  2003-03       Impact factor: 5.852

10.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  8 in total

1.  An Overview of Class II Phosphoinositide 3-Kinases.

Authors:  Emily Yan Zhi Heng; Tania Maffucci
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

2.  The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia.

Authors:  Renée Beekman; Vicente Chapaprieta; Núria Russiñol; Roser Vilarrasa-Blasi; Núria Verdaguer-Dot; Joost H A Martens; Martí Duran-Ferrer; Marta Kulis; François Serra; Biola M Javierre; Steven W Wingett; Guillem Clot; Ana C Queirós; Giancarlo Castellano; Julie Blanc; Marta Gut; Angelika Merkel; Simon Heath; Anna Vlasova; Sebastian Ullrich; Emilio Palumbo; Anna Enjuanes; David Martín-García; Sílvia Beà; Magda Pinyol; Marta Aymerich; Romina Royo; Montserrat Puiggros; David Torrents; Avik Datta; Ernesto Lowy; Myrto Kostadima; Maša Roller; Laura Clarke; Paul Flicek; Xabier Agirre; Felipe Prosper; Tycho Baumann; Julio Delgado; Armando López-Guillermo; Peter Fraser; Marie-Laure Yaspo; Roderic Guigó; Reiner Siebert; Marc A Martí-Renom; Xose S Puente; Carlos López-Otín; Ivo Gut; Hendrik G Stunnenberg; Elias Campo; Jose I Martin-Subero
Journal:  Nat Med       Date:  2018-05-21       Impact factor: 53.440

Review 3.  Susceptibility to Tuberculosis Is Associated With PI3K-Dependent Increased Mobilization of Neutrophils.

Authors:  Gina R Leisching
Journal:  Front Immunol       Date:  2018-07-17       Impact factor: 7.561

4.  Hypoxia regulates human mast cell adhesion to fibronectin via the PI3K/AKT signaling pathway.

Authors:  Joanna Pastwińska; Aurelia Walczak-Drzewiecka; Magdalena Łukasiak; Marcin Ratajewski; Jarosław Dastych
Journal:  Cell Adh Migr       Date:  2020-12       Impact factor: 3.405

Review 5.  The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy.

Authors:  Mohammad Hossein Pourhanifeh; Rezvan Mohammadi; Somaye Noruzi; Seyede Atefe Hosseini; Sahar Fanoudi; Yousef Mohamadi; Milad Hashemzehi; Zatollah Asemi; Hamid Reza Mirzaei; Reza Salarinia; Hamed Mirzaei
Journal:  Cancer Cell Int       Date:  2019-06-10       Impact factor: 5.722

6.  A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.

Authors:  Guillem Clot; Pedro Jares; Eva Giné; Alba Navarro; Cristina Royo; Magda Pinyol; David Martín-Garcia; Santiago Demajo; Blanca Espinet; Antonio Salar; Ana Ferrer; Ana Muntañola; Marta Aymerich; Hilka Rauert-Wunderlich; Elaine S Jaffe; Joseph M Connors; Randy D Gascoyne; Jan Delabie; Armando López-Guillermo; German Ott; George W Wright; Louis M Staudt; Andreas Rosenwald; David W Scott; Lisa M Rimsza; Sílvia Beà; Elías Campo
Journal:  Blood       Date:  2018-05-16       Impact factor: 25.476

7.  Subclones in B-lymphoma cell lines: isogenic models for the study of gene regulation.

Authors:  Hilmar Quentmeier; Claudia Pommerenke; Ole Ammerpohl; Robert Geffers; Vivien Hauer; Roderick A F MacLeod; Stefan Nagel; Julia Romani; Emanuela Rosati; Anders Rosén; Cord C Uphoff; Margarete Zaborski; Hans G Drexler
Journal:  Oncotarget       Date:  2016-09-27

8.  Dynamic Bayesian networks for prediction of health status and treatment effect in patients with chronic lymphocytic leukemia.

Authors:  Piotr Ladyzynski; Maria Molik; Piotr Foltynski
Journal:  Sci Rep       Date:  2022-02-02       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.